<DOC>
	<DOCNO>NCT00810693</DOCNO>
	<brief_summary>The aim study assess efficacy safety different dose BAY63-2521 give orally 12 week , patient symptomatic Pulmonary Arterial Hypertension ( PAH ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Oral BAY63-2521 Patients With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Male female patient symptomatic PAH ( Idiopathic , Familial , Associated PAH due connective tissue disease , congenital heart disease , portal hypertension liver cirrhosis , due anorexigen amphetamine use ) Treatment naive patient patient pretreated Endothelin Antagonist Prostacyclinanalogue ( except I.V. ) . All type pulmonary hypertension except subtypes Venice Group I specify inclusion criterion , severe COPD ( chronic obstructive pulmonary disease ) , uncontrolled arterial hypertension , leave heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>PH</keyword>
	<keyword>Stimulator</keyword>
</DOC>